GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Korro Bio Inc (NAS:KRRO) » Definitions » Pretax Margin %

Korro Bio (Korro Bio) Pretax Margin % : % (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Korro Bio Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Korro Bio's Pre-Tax Income for the six months ended in Jun. 2023 was $-37.25 Mil. Korro Bio's Revenue for the six months ended in Jun. 2023 was $0.00 Mil. Therefore, Korro Bio's pretax margin for the quarter that ended in Jun. 2023 was %.

The historical rank and industry rank for Korro Bio's Pretax Margin % or its related term are showing as below:


KRRO's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.52
* Ranked among companies with meaningful Pretax Margin % only.

Korro Bio Pretax Margin % Historical Data

The historical data trend for Korro Bio's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korro Bio Pretax Margin % Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23
Pretax Margin %
- - -

Korro Bio Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Pretax Margin % - - - - -

Competitive Comparison of Korro Bio's Pretax Margin %

For the Biotechnology subindustry, Korro Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korro Bio's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Korro Bio's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Korro Bio's Pretax Margin % falls into.



Korro Bio Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Korro Bio's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-81.145/0
= %

Korro Bio's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-37.254/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korro Bio  (NAS:KRRO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Korro Bio Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Korro Bio's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Korro Bio (Korro Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 17 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Steve Colletti officer: Chief Scientific Officer C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139
Shelby J. Walker officer: See Remarks C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139

Korro Bio (Korro Bio) Headlines

From GuruFocus

Korro Announces $70 Million Private Placement

By Marketwired 04-18-2024